Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 17, 2016, Pages E2421-E2429

  Kagiava, Alexia ^a   Sargiannidou, Irene ^a   Theophilidis, George ^b   Karaiskos, Christos ^a   Richter, Jan ^a   Bashiardes, Stavros ^a   Schiza, Natasa ^a   Nearchou, Marianna ^a   Christodoulou, Christina ^a   Scherer, Steven S ^c   Kleopa, Kleopas A ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Charcot Marie Tooth disease; Connexin32; Demyelinating neuropathy; Gene therapy; Peripheral nerve

Indexed keywords

CONNEXIN 32; LENTIVIRUS VECTOR; MYELIN;

ACTION POTENTIAL; ARTICLE; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DEMYELINATING PERIPHERAL NEUROPATHY; DORSAL ROOT; GENE EXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOTOR PERFORMANCE; MOUSE; MUSCLE CONTRACTILITY; MYELIN SHEATH; MYELINATED NERVE; NERVE CONDUCTION VELOCITY; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMOTER REGION; QUADRICEPS FEMORIS MUSCLE; SCHWANN CELL; SCIATIC NERVE; SPINAL GANGLION; SPINAL ROOT; TRIGEMINAL NERVE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DEMYELINATING DISEASE; GENE THERAPY; GENETICS; HUMAN; METABOLISM;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; DEMYELINATING DISEASES; GENETIC THERAPY; HUMANS; MYELIN SHEATH; SCHWANN CELLS;

EID: 84964720167     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522202113     Document Type: Article

References (46)

1. Saporta MA, Shy ME (2013) Inherited peripheral neuropathies. Neurol Clin 31(2):597-619.
2. Baets J, De Jonghe P, Timmerman V (2014) Recent advances in Charcot-Marie-Tooth disease. Curr Opin Neurol 27(5):532-540.
3. Harel T, Lupski JR (2014) Charcot-Marie-Tooth disease and pathways to molecularbased therapies. Clin Genet 86(5):422-431.
4. Bouhy D, Timmerman V (2013) Animal models and therapeutic prospects for Charcot-Marie-Tooth disease. Ann Neurol 74(3):391-396.
5. Homs J, et al. (2011) Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration. Gene Ther 18(6):622-630.
6. Federici T, et al. (2009) Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer. Genet Vaccines Ther 7:1.
7. Gonzalez S, Fernando RN, Perrin-Tricaud C, Tricaud N (2014) In vivo introduction of transgenes into mouse sciatic nerve cells in situ using viral vectors. Nat Protoc 9(5): 1160-1169.
8. Sargiannidou I, et al. (2015) Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. Ann Neurol 78(2):303-316.
9. Scherer SS, et al. (2005) Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice. J Neurosci 25(6): 1550-1559.
10. Anzini P, et al. (1997) Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin J Neurosci 17(12):4545-4551.
11. Scherer SS, et al. (1998) Connexin32-null mice develop demyelinating peripheral neuropathy. Glia 24(1):8-20.
12. Kleopa KA, Scherer SS (2006) Molecular genetics of X-linked Charcot-Marie-Tooth disease. Neuromolecular Med 8(1-2):107-122.
13. Scherer SS, et al. (1995) Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci 15(12):8281-8294.
14. Sargiannidou I, et al. (2009) Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects. J Neurosci 29(15):4736-4749.
15. Vavlitou N, et al. (2010) Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie-Tooth neuropathy. J Neuropathol Exp Neurol 69(9):945-958.
16. Kobsar I, et al. (2003) Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126(Pt 4): 804-813.
17. Wang Ip C, et al. (2006) Role of immune cells in animal models for inherited peripheral neuropathies. Neuromolecular Med 8(1-2):175-190.
18. Haller FR, Low FN (1971) The fine structure of the peripheral nerve root sheath in the subarachnoid space in the rat and other laboratory animals. Am J Anat 131(1):1-19.
19. McCabe JS, Low FN (1969) The subarachnoid angle: An area of transition in peripheral nerve. Anat Rec 164(1):15-33.
20. Mellick R, Cavanagh JB (1967) Longitudinal movement of radioiodinated albumin within extravascular spaces of peripheral nerves following three systems of experimental trauma. J Neurol Neurosurg Psychiatry 30(5):458-463.
21. Low PA (1985) Endoneurial potassium is increased and enhances spontaneous activity in regenerating mammalian nerve fibers: Implications for neuropathic positive symptoms. Muscle Nerve 8(1):27-33.
22. Mizisin AP, Weerasuriya A (2011) Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol 121(3):291-312.
23. Vulchanova L, et al. (2010) Differential adeno-Associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol Pain 6:31.
24. Glatzel M, et al. (2000) Adenoviral and adeno-Associated viral transfer of genes to the peripheral nervous system. Proc Natl Acad Sci USA 97(1):442-447.
25. Beutler AS, Banck MS, Walsh CE, Milligan ED (2005) Intrathecal gene transfer by adeno-Associated virus for pain. Curr Opin Mol Ther 7(5):431-439.
26. Jacques SJ, et al. (2012) AAV8(gfp) preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection. Mol Cell Neurosci 49(4):464-474.
27. Bevan AK, et al. (2011) Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19(11):1971-1980.
28. Fedorova E, Battini L, Prakash-Cheng A,Marras D, Gusella GL (2006) Lentiviral gene delivery to CNS by spinal intrathecal administration to neonatal mice. J Gene Med 8(4):414-424.
29. Dengler EC, et al. (2014) Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain. J Neuroinflammation 11:92.
30. Luo MC, et al. (2005) An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 1:29.
31. Song Z, Zou W, Liu C, Guo Q (2010) Gene knockdown with lentiviral vector-mediated intrathecal RNA interference of protein kinase C gamma reverses chronic morphine tolerance in rats. J Gene Med 12(11):873-880.
32. Lepore AC, Bakshi A, Swanger SA, Rao MS, Fischer I (2005) Neural precursor cells can be delivered into the injured cervical spinal cord by intrathecal injection at the lumbar cord. Brain Res 1045(1-2):206-216.
33. Watson G, et al. (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 13(11):917-925.
34. Duque SI, et al. (2015) A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol 77(3):399-414.
35. Kleopa KA (2011) The role of gap junctions in Charcot-Marie-Tooth disease. J Neurosci 31(49):17753-17760.
36. Shy ME, et al. (2007) CMT1X phenotypes represent loss of GJB1 gene function. Neurology 68(11):849-855.
37. Lattanzi A, et al. (2014) Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Hum Mol Genet 23(12):3250-3268.
38. Biffi A, et al. (2011) Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117(20):5332-5339.
39. Biffi A, et al. (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341(6148):1233158.
40. Christodoulou I, et al. (2016) Measurement of lentiviral vector titre and copy number by cross-species duplex quantitative PCR. Gene Ther 23(1):113-118.
41. Geraerts M, Willems S, Baekelandt V, Debyser Z, Gijsbers R (2006) Comparison of lentiviral vector titration methods. BMC Biotechnol 6:34.
42. Savvaki M, et al. (2010) The expression of TAG-1 in glial cells is sufficient for the formation of the juxtaparanodal complex and the phenotypic rescue of tag-1 homozygous mutants in the CNS. J Neurosci 30(42):13943-13954.
43. Britt JM, et al. (2010) Polyethylene glycol rapidly restores axonal integrity and improves the rate of motor behavior recovery after sciatic nerve crush injury. J Neurophysiol 104(2):695-703.
44. Pratt SJ, Lovering RM (2014) A stepwise procedure to test contractility and susceptibility to injury for the rodent quadriceps muscle. J Biol Methods 1(2):e8.
45. Ahn M, et al. (2008) Cx29 and Cx32, two connexins expressed by myelinating glia, do not interact and are functionally distinct. J Neurosci Res 86(5):992-1006.
46. Groh J, et al. (2010) Attenuation of MCP-1/CCL2 expression ameliorates neuropathy in a mouse model for Charcot-Marie-Tooth 1X. Hum Mol Genet 19(18):3530-3543.